Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 02	LMEDLINE coverage updated
NEWS	3	JUL 02	SCISEARCH enhanced with complete author names
NEWS	4	JUL 02	CHEMCATS accession numbers revised
NEWS	5	JUL 02	CA/CAplus enhanced with utility model patents from China
NEWS	6	JUL 16	CAplus enhanced with French and German abstracts
NEWS	7	JUL 18	CA/CAplus patent coverage enhanced
NEWS	8	JUL 26	USPATFULL/USPAT2 enhanced with IPC reclassification
NEWS	9	JUL 30	USGENE now available on STN
NEWS	10	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	11	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	12	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS	13	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS	14	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	15	AUG 27	USPATOLD now available on STN
NEWS	16	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	17	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	18	SEP 13	FORIS renamed to SOFIS
NEWS	19	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	20	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS	21	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS	22	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	23	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	24	OCT 19	BEILSTEIN updated with new compounds
NEWS	25	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	26	NOV 19	WPIX enhanced with XML display format
NEWS	27	NOV 30	ICSD reloaded with enhancements
NEWS	28	DEC 04	LINPADOCDB now available on STN

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:50:11 ON 06 DEC 2007

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 10:50:37 ON 06 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2007 HIGHEST RN 956828-07-2
DICTIONARY FILE UPDATES: 5 DEC 2007 HIGHEST RN 956828-07-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10780797_1MT.str



chain nodes :
10 11 12 13 14 15 16 17 18 19
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
1-18 2-17 3-16 4-15 7-10 8-19 9-12 10-11 11-13 11-14
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-9 7-8 8-9

exact/norm bonds :
5-7 6-9 7-8 8-9 11-14
exact bonds :
1-18 2-17 3-16 4-15 7-10 8-19 9-12 10-11 11-13
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 10:50:52 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 5060 TO ITERATE

100.0% PROCESSED 5060 ITERATIONS 8 ANSWERS
SEARCH TIME: 00.00.01

L2 8 SEA SSS FUL L1

=> d scan

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN D-Tryptophan, 1-methyl-, monohydrochloride (9CI)
MF C12 H14 N2 O2 . Cl H

Absolute stereochemistry.



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tryptophan, 1-methyl-, picrate (6CI)
MF C12 H14 N2 O2 . C6 H3 N3 O7

CM 1

Absolute stereochemistry.



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 8 ANSWERS REGISTRY COPYRIGHT 2007 ACS on STN
IN Tryptophan, N-methyl-t3-, DL- (7CI)
MF C12 H11 N2 O2 T3



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

```
=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   172.10     172.31

FILE 'MEDLINE' ENTERED AT 10:51:25 ON 06 DEC 2007

FILE 'CAPLUS' ENTERED AT 10:51:25 ON 06 DEC 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:51:25 ON 06 DEC 2007
COPYRIGHT (C) 2007 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 10:51:25 ON 06 DEC 2007
CA INDEXING COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l1
SUBSTANCE QUERIES NOT VALID IN THIS FILE
The logic expression entered contains L#s or saved query names which
correspond to structures built by the STRUCTURE command or to screen
sets.  These must be searched in a substance file such as the REGISTRY
file.  In some files you may use a Registry Number answer set from a
structure search as a search term or profile in some bibliographic
file containing Registry Numbers, e.g.  the CA file.  For an
explanation, enter "HELP CROSSOVER" at an arrow prompt (=>).

=> s l2
SAMPLE SEARCH INITIATED 10:51:34 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED -       11 TO ITERATE

100.0% PROCESSED       11 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:           11 TO      209
PROJECTED ANSWERS:               0 TO        0

L3         204 L2

=> s l3 and (cancer? or tumor? or neoplas?)
L4          38 L3 AND (CANCER? OR TUMOR? OR NEOPLAS?)

=> s l4 and cyclophosphamide
L5          10 L4 AND CYCLOPHOSPHAMIDE

=> d l5 1-10 ibib, abs, hitstr
```

NPA (not prior Art)

```
L5   ANSWER 1 OF 10  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:60697  CAPLUS
DOCUMENT NUMBER:          146:243247
TITLE:                    Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic
                          Cells by Stereoisomers of 1-Methyl-Tryptophan
                          Correlates with Antitumor Responses
AUTHOR(S):                Hou, De-Yan; Muller, Alexander J.; Sharma, Madhav D.;
                          DuHadaway, James; Banerjee, Tinku; Johnson, Maribeth;
                          Mellor, Andrew L.; Prendergast, George C.; Munn, David
                          H.
CORPORATE SOURCE:         Immunotherapy Center and Departments of Pediatrics,
                          Medicine, and Biostatistics, Medical College of
                          Georgia, Augusta, GA, USA
SOURCE:                   Cancer Research (2007), 67(2), 792-801
                          CODEN: CNREA8; ISSN: 0008-5472
```

PUBLISHER: American Association for Cancer Research
DOCUMENT TYPE: Journal
LANGUAGE: English

AB Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme that contributes to tolerance in a number of biol. settings. In cancer, IDO activity may help promote acquired tolerance to tumor antigens. The IDO inhibitor 1-methyl-tryptophan is being developed for clin. trials. However, 1-methyl-tryptophan exists in two stereoisomers with potentially different biol. properties, and it has been unclear which isomer might be preferable for initial development. In this study, we provide evidence that the D and L stereoisomers exhibit important cell type-specific variations in activity. The L isomer was the more potent inhibitor of IDO activity using the purified enzyme and in HeLa cell-based assays. However, the D isomer was significantly more effective in reversing the suppression of T cells created by IDO-expressing dendritic cells, using both human monocyte-derived dendritic cells and murine dendritic cells isolated directly from tumor-draining lymph nodes. In vivo, the D isomer was more efficacious as an anticancer agent in chemo-immunotherapy regimens using cyclophosphamide, paclitaxel, or gemcitabine, when tested in mouse models of transplantable melanoma and transplantable and autochthonous breast cancer. The D isomer of 1-methyl-tryptophan specifically targeted the IDO gene because the antitumor effect of D-1-methyl-tryptophan was completely lost in mice with a disruption of the IDO gene (IDO-knockout mice). Taken together, our findings support the suitability of D-1-methyl-tryptophan for human trials aiming to assess the utility of IDO inhibition to block host-mediated immunosuppression and enhance antitumor immunity in the setting of combined chemo-immunotherapy regimens.

IT 21339-55-9, L-1-Methyl-tryptophan 110117-83-4, D-1-Methyl-tryptophan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-Me-tryptophan correlates with antitumor responses)

RN 21339-55-9 CAPLUS
CN L-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 110117-83-4 CAPLUS
CN D-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

NPA

L5 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1157586 CAPLUS
DOCUMENT NUMBER: 145:465678
TITLE: Compositions and methods for cancer immunotherapy
INVENTOR(S): Rossignol, Daniel P.; Ishizaka, Sally T.; Hawkins, Lynn D.; Fields, Scott
PATENT ASSIGNEE(S): Eisai Co., Ltd, Japan
SOURCE: PCT Int. Appl., 85pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006116423	A2	20061102	WO 2006-US15668	20060426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2006241206	A1	20061102	AU 2006-241206	20060426
US 2007020232	A1	20070125	US 2006-411332	20060426
PRIORITY APPLN. INFO.:			US 2005-674680P	P 20050426
			WO 2006-US15668	W 20060426

AB The invention relates to immunotherapeutic compds., mainly TLR agonists, tumor vaccines, and therapeutic antibodies, and methods for stimulating an immune response in an individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer. Also, the compds. of the invention can be administered as a prophylactic to an individual to prevent or delay the development of cancer.

IT 21339-55-9, 1-Methyl tryptophan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. and methods for cancer immunotherapy)
RN 21339-55-9 CAPLUS
CN L-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



INSTANT APP

L5 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1019533 CAPLUS
DOCUMENT NUMBER: 141:420433
TITLE: Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities in the

treatment of cancer and infection

INVENTOR(S): Munn, David; Mellor, Andrew

PATENT ASSIGNEE(S): Medical College of Georgia Research Institute, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004234623	A1	20041125	US 2004-780797		20040217
US 2005186289	A1	20050825	US 2004-780150		20040217
PRIORITY APPLN. INFO.:			US 2003-459489P	P	20030401
			US 2004-538647P	P	20040122

AB The invention discloses a method for treating a subject with a cancer or an infection, the method including administering an inhibitor of indoleamine-2,3-dioxygenase (IDO) in an amount effective to reverse IDO-mediated immunosuppression, and administering at least one addnl. therapeutic agent, wherein the administration of the inhibitor of IDO and the at least one addnl. therapeutic agent demonstrate therapeutic synergy.

IT 21339-55-9, 1-Methyl-tryptophan 26988-72-7
110117-83-4
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(indoleamine dioxygenase inhibitors combined with other therapeutic modalities for treatment of cancer and infection)

RN 21339-55-9 CAPLUS

CN L-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 26988-72-7 CAPLUS

CN Tryptophan, 1-methyl- (CA INDEX NAME)



RN 110117-83-4 CAPLUS

CN D-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:927197 CAPLUS
DOCUMENT NUMBER: 141:388648
TITLE: Novel ido (indoleamine 2,3-dioxygenase) inhibitors and methods of use
INVENTOR(S): Prendergast, George C.; Muller, Alexander J.; Duhadaway, James B.; Malachowski, William
PATENT ASSIGNEE(S): Lankenau Institute for Medical Research, USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004094409	A1	20041104	WO 2004-US5154		20040220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2520586	A1	20041104	CA 2004-2520586		20040220
EP 1606285	A1	20051221	EP 2004-713430		20040220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
CN 1795187	A	20060628	CN 2004-80008331		20040220
CN 1794986	A	20060628	CN 2004-80014321		20040220
JP 2006521377	T	20060921	JP 2006-508788		20040220
US 2007173524	A1	20070726	US 2006-550444		20060601
PRIORITY APPLN. INFO.:			US 2003-458162P	P	20030327
			US 2003-527449P	P	20031205
			WO 2004-US5154	W	20040220

OTHER SOURCE(S): MARPAT 141:388648

AB Novel inhibitors of indoleamine 2,3-dioxygenase (IDO) activity are provided. In yet another embodiment of the present invention, a combination treatment protocol comprising administration of an IDO inhibitor with a signal transduction inhibitor (STI) or chemotherapeutic agent is provided, which is effective for suppressing tumor growth. In still another embodiment of the present invention, a combination treatment protocol is provided for the treatment of a chronic viral infection, comprising the administration of an IDO inhibitor and a chemotherapeutic agent.

IT 21339-55-9, 1-Methyltryptophan 26988-72-7, 1-DL-Methyltryptophan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel indoleamine dioxygenase inhibitors for treatment of

tumors and viral infections and combination with chemotherapeutic agents and signal transduction inhibitors)

RN 21339-55-9 CAPLUS
CN L-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 26988-72-7 CAPLUS
CN Tryptophan, 1-methyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:927043 CAPLUS
DOCUMENT NUMBER: 141:388646
TITLE: Novel methods for the treatment of cancer and viral infections
INVENTOR(S): Prendergast, George C.; Muller, Alexander J.; Duhadaway, James B.; Malachowski, William
PATENT ASSIGNEE(S): Lankenau Institute for Medical Research, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004093871	A1	20041104	WO 2004-US5155	20040220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2520172	A1	20041104	CA 2004-2520172	20040220
EP 1613308	A1	20060111	EP 2004-713378	20040220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1795187	A	20060628	CN 2004-80008331	20040220

CN 1794986	A	20060628	CN 2004-80014321		20040220
JP 2006521378	T	20060921	JP 2006-508789		20040220
US 2007099844	A1	20070503	US 2006-551151		20060518
PRIORITY APPLN. INFO.:			US 2003-458162P	P	20030327
			US 2003-527449P	P	20031205
			WO 2004-US5155	W	20040220

AB Compns. and methods for the treatment of malignancy and chronic viral infection are disclosed. A method is claimed for treating a cancer comprising administering at least one indoleamine 2,3-dioxygenase (IDO) inhibitor and at least one signal transduction inhibitor (STI). A method is claimed for treating a cancer comprising administering at least one immunomodulator, other than IDO inhibitor, and at least one cytotoxic chemotherapeutic agent or at least one STI. A method for treating a chronic viral infection in a patient is claimed comprising administering at least one IDO inhibitor and at least one chemotherapeutic agent. Pharmaceutical compns. containing compds. of the invention for treating cancer and viral infections are also claimed.

IT 21339-55-9, 1-Methyltryptophan 26988-72-7, 1-Methyl-DL-tryptophan
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(treatment of cancer and viral infections using indoleamine 2,3-dioxygenase inhibitors, signal transduction inhibitors, chemotherapeutic agents, and immunomodulators)

RN 21339-55-9 CAPLUS
CN L-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 26988-72-7 CAPLUS
CN Tryptophan, 1-methyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2007:198176 USPATFULL
TITLE: "Novel ido inhibitors and methods of use
INVENTOR(S): Prendergast, George C., Bala Cynwyd, PA, UNITED STATES
Muller, Alexander J., Media, PA, UNITED STATES
Duhadaway, James B., Wilmington, DE, UNITED STATES
Malachowski, William, Collegeville, PA, UNITED STATES

NUMBER	KIND	DATE

DOES NOT ENCOMPASS 1-MT

PATENT INFORMATION:	US 2007173524	A1	20070726
APPLICATION INFO.:	US 2004-550444	A1	20040220 (10)
	WO 2004-US5154		20040220
			20060601 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-458162P	20030327 (60)
	US 2003-527449P	20031205 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400, PHILADELPHIA, PA, 19103-2307, US
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 31 Drawing Page(s)
LINE COUNT: 1893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds, compositions and methods for the treatment of malignancy are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 21339-55-9, 1-Methyltryptophan 26988-72-7, 1-Methyl-DL-tryptophan
(treatment of cancer and viral infections using indoleamine 2,3-dioxygenase inhibitors, signal transduction inhibitors, chemotherapeutic agents, and immunomodulators)
RN 21339-55-9 USPATFULL
CN L-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 26988-72-7 USPATFULL
CN Tryptophan, 1-methyl- (CA INDEX NAME)



L5 ANSWER 7 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2007:114770 USPATFULL
TITLE: Novel methods for the treatment of cancer
INVENTOR(S): Prendergast, George C., Bala-Cynwyd, PA, UNITED STATES
Muller, Alexander J., Media, PA, UNITED STATES
Duhadaway, James B., Wilmington, DE, UNITED STATES
Malachowski, William, Collegeville, PA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION: US 2007099844 A1 20070503
APPLICATION INFO.: US 2004-551151 A1 20040220 (10)
WO 2004-US5155 20040220
20060518 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-458162P	20030327 (60)
	US 2003-527449P	20031205 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400, PHILADELPHIA, PA, 19103-2307, US
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 1319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the treatment of malignancy and chronic viral infection are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 21339-55-9, 1-Methyltryptophan 26988-72-7, 1-Methyl-DL-tryptophan
(treatment of cancer and viral infections using indoleamine 2,3-dioxygenase inhibitors, signal transduction inhibitors, chemotherapeutic agents, and immunomodulators)
RN 21339-55-9 USPATFULL
CN L-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 26988-72-7 USPATFULL
CN Tryptophan, 1-methyl- (CA INDEX NAME)



NP17

L5 ANSWER 8 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2007:23191 USPATFULL
TITLE: Compositions and methods for cancer immunotherapy
INVENTOR(S): Rossignol, Daniel P., Ridgefield Park, NJ, UNITED STATES
Ishizaka, Sally T., Andover, MA, UNITED STATES
Hawkins, Lynn D., Andover, MA, UNITED STATES
Fields, Scott, Ridgefield Park, NJ, UNITED STATES
PATENT ASSIGNEE(S): Eisai Co., Ltd., Tokyo, JAPAN, 112-88 (non-U.S.

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007020232	A1	20070125
APPLICATION INFO.:	US 2006-411332	A1	20060426 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-674680P	20050426 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 21339-55-9, 1-Methyl tryptophan
(compns. and methods for cancer immunotherapy)
RN 21339-55-9 USPATFULL
CN L-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 9 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2005:214617 USPATFULL
TITLE: Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase
INVENTOR(S): Munn, David, Augusta, GA, UNITED STATES
Mellor, Andrew, Augusta, GA, UNITED STATES
PATENT ASSIGNEE(S): Medical College of Georgia Research Institute, Inc., Augusta, GA, UNITED STATES, 30912 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005186289	A1	20050825
APPLICATION INFO.:	US 2004-780150	A1	20040217 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-538647P	20040122 (60)
	US 2003-459489P	20030401 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN, 55458, US
NUMBER OF CLAIMS: 47
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2455
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides improved treatment methods by the administration of the non-physiologic D-isomer of an IDO inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 21339-55-9, 1-Methyl-tryptophan 26988-72-7
110117-83-4
(indoleamine dioxygenase inhibitors combined with other therapeutic modalities for treatment of cancer and infection)
RN 21339-55-9 USPATFULL
CN L-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 26988-72-7 USPATFULL
CN Tryptophan, 1-methyl- (CA INDEX NAME)



RN 110117-83-4 USPATFULL
CN D-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 10 OF 10 USPATFULL on STN
ACCESSION NUMBER: 2004:298760 USPATFULL
TITLE: Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
INVENTOR(S): Munn, David, Augusta, GA, UNITED STATES
Mellor, Andrew, Augusta, GA, UNITED STATES
PATENT ASSIGNEE(S): Medical College of Georgia Research Institute, Inc., Augusta, GA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004234623	A1	20041125	
APPLICATION INFO.:	US 2004-780797	A1	20040217	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-538647P	20040122 (60)
	US 2003-459489P	20030401 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN, 55458
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 21339-55-9, 1-Methyl-tryptophan 26988-72-7
110117-83-4
(indoleamine dioxygenase inhibitors combined with other therapeutic modalities for treatment of cancer and infection)
RN 21339-55-9 USPATFULL
CN L-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 26988-72-7 USPATFULL
CN Tryptophan, 1-methyl- (CA INDEX NAME)



RN 110117-83-4 USPATFULL
CN D-Tryptophan, 1-methyl- (CA INDEX NAME)

Absolute stereochemistry.




```
=> d his

     (FILE 'HOME' ENTERED AT 10:50:11 ON 06 DEC 2007)

     FILE 'REGISTRY' ENTERED AT 10:50:37 ON 06 DEC 2007
L1              STRUCTURE UPLOADED
L2            8 S L1 FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:51:25 ON 06 DEC
     2007
L3          204 S L2
L4           38 S L3 AND (CANCER? OR TUMOR? OR NEOPLAS?)
L5           10 S L4 AND CYCLOPHOSPHAMIDE

=> d l4 1-38 ibib, abs

L4   ANSWER 1 OF 38  CAPLUS  COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER:         2007:843527  CAPLUS
DOCUMENT NUMBER:          147:400343
TITLE:                    Novel Tryptophan Catabolic Enzyme IDO2 Is the
                          Preferred Biochemical Target of the Antitumor
                          Indoleamine 2,3-Dioxygenase Inhibitory Compound
                          D-1-Methyl-Tryptophan
AUTHOR(S):                Metz, Richard; DuHadaway, James B.; Kamasani, Uma;
                          Laury-Kleintop, Lisa; Muller, Alexander J.;
                          Prendergast, George C.
CORPORATE SOURCE:         Lankenau Institute for Medical Research, Wynnewood,
                          PA, 19096, USA
SOURCE:                   Cancer Research (2007), 67(15), 7082-7087
                          CODEN: CNREA8; ISSN: 0008-5472
PUBLISHER:                American Association for Cancer Research
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   Small-mol. inhibitors of indoleamine 2,3-dioxygenase (IDO) are currently
     being translated to clinic for evaluation as cancer
     therapeutics. One issue related to trials of the clin. lead inhibitor,
     D-1-methyl-tryptophan (D-1MT), concerns the extent of its biochem.
     specificity for IDO. Here, we report the discovery of a novel IDO-related
     Trp catabolic enzyme termed IDO2 that is preferentially inhibited by
     D-1MT. IDO2 is not as widely expressed as IDO but like its relative is
     also expressed in antigen-presenting dendritic cells where Trp catabolism
     drives immune tolerance. We identified 2 common genetic polymorphisms in
     the human gene encoding IDO2 that ablate its enzymic activity. Like IDO,
     IDO2 catabolizes Trp, triggers phosphorylation of the translation
     initiation factor eIF2α, and (reported here for the first time)
     mobilizes translation of LIP, an inhibitory isoform of the immune
     regulatory transcription factor NF-IL6. Tryptophan restoration switches
     off this signaling pathway when activated by IDO, but not IDO2, arguing
     that IDO2 has a distinct signaling role. Our findings have implications
     for understanding the evolution of tumoral immune tolerance and
     for interpreting preclin. and clin. responses to D-1MT or other IDO
     inhibitors being developed to treat cancer, chronic infection,
     and other diseases.
```

REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:790312 CAPLUS
DOCUMENT NUMBER: 147:187318
TITLE: Indoleamine 2,3-dioxygenase inhibitor for enhancing immune response against tumor or infection and tryptophan metabolic product for suppressing immune response against transplant rejection and autoimmune disease
INVENTOR(S): Chen, Wei; Blazar, Bruce R.; Munn, David; Mellor, Andrew
PATENT ASSIGNEE(S): Medical College of Georgia Research Institute, Inc., USA
SOURCE: PCT Int. Appl., 93pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007081878	A2	20070719	WO 2007-US404	20070105

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-756861P P 20060107
AB The present invention provides methods for the control of the generation of regulatory T cells (Tregs) and uses thereof. Indoleamine 2,3-dioxygenase inhibitor e.g. 1-methyl-tryptophan is used to reduce immunosuppression mediated by regulatory T cells and to enhance immune response to vaccine, e.g. tumor or viral antigen. The invention also uses metabolic product of tryptophan for inducing regulatory T cells to increase immunosuppression and antigen tolerance to prevent and treat allograft or transplant rejection and autoimmune disease.

L4 ANSWER 3 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2007:483054 CAPLUS
DOCUMENT NUMBER: 146:475678
TITLE: Indoleamine 2,3-dioxygenase modulation by TLR ligands and immunomodulatory uses thereof
INVENTOR(S): Mellor, Andrew; Munn, David
PATENT ASSIGNEE(S): Medical College of Georgia Research Institute, Inc., USA
SOURCE: PCT Int. Appl., 46pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007050405	A2	20070503	WO 2006-US40796	20061020

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-729041P P 20051021

AB The induction of indoleamine 2,3-dioxygenase (IDO) in an IDO-competent subset of dendritic cells by TLR ligands, including TLR9 ligands, and various uses thereof, are presented. Also presented are e.g. a method for enhancing an immune response by administration of a TLR9 agonist and an IDO inhibitor.

L4 ANSWER 4 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2007:60697 CAPLUS

DOCUMENT NUMBER: 146:243247

TITLE: Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses

AUTHOR(S): Hou, De-Yan; Muller, Alexander J.; Sharma, Madhav D.; DuHadaway, James; Banerjee, Tinku; Johnson, Maribeth; Mellor, Andrew L.; Prendergast, George C.; Munn, David H.

CORPORATE SOURCE: Immunotherapy Center and Departments of Pediatrics, Medicine, and Biostatistics, Medical College of Georgia, Augusta, GA, USA

SOURCE: Cancer Research (2007), 67(2), 792-801
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Indoleamine 2,3-dioxygenase (IDO) is an immunosuppressive enzyme that contributes to tolerance in a number of biol. settings. In cancer, IDO activity may help promote acquired tolerance to tumor antigens. The IDO inhibitor 1-methyl-tryptophan is being developed for clin. trials. However, 1-methyl-tryptophan exists in two stereoisomers with potentially different biol. properties, and it has been unclear which isomer might be preferable for initial development. In this study, we provide evidence that the D and L stereoisomers exhibit important cell type-specific variations in activity. The L isomer was the more potent inhibitor of IDO activity using the purified enzyme and in HeLa cell-based assays. However, the D isomer was significantly more effective in reversing the suppression of T cells created by IDO-expressing dendritic cells, using both human monocyte-derived dendritic cells and murine dendritic cells isolated directly from tumor-draining lymph nodes. In vivo, the D isomer was more efficacious as an anticancer agent in chemo-immunotherapy regimens using cyclophosphamide, paclitaxel, or gemcitabine, when tested in mouse models of transplantable melanoma and transplantable and autochthonous breast cancer. The D isomer of 1-methyl-tryptophan specifically targeted the IDO gene because the antitumor effect of D-1-methyl-tryptophan was completely lost in mice with a disruption of the IDO gene (IDO-knockout mice). Taken together, our findings support the suitability of D-1-methyl-tryptophan for human trials aiming to assess the utility of IDO inhibition to block host-mediated immunosuppression and enhance antitumor immunity in the setting of combined chemo-immunotherapy regimens.

REFERENCE COUNT: 52 THERE ARE 52 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:1157586 CAPLUS
DOCUMENT NUMBER: 145:465678
TITLE: Compositions and methods for cancer immunotherapy
INVENTOR(S): Rossignol, Daniel P.; Ishizaka, Sally T.; Hawkins, Lynn D.; Fields, Scott
PATENT ASSIGNEE(S): Eisai Co., Ltd, Japan
SOURCE: PCT Int. Appl., 85pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2006116423	A2	20061102	WO 2006-US15668		20060426
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM					
AU 2006241206	A1	20061102	AU 2006-241206		20060426
US 2007020232	A1	20070125	US 2006-411332		20060426
PRIORITY APPLN. INFO.:			US 2005-674680P	P	20050426
			WO 2006-US15668	W	20060426

AB The invention relates to immunotherapeutic compds., mainly TLR agonists, tumor vaccines, and therapeutic antibodies, and methods for stimulating an immune response in an individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer. Also, the compds. of the invention can be administered as a prophylactic to an individual to prevent or delay the development of cancer.

L4 ANSWER 6 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:766252 CAPLUS
DOCUMENT NUMBER: 145:327886
TITLE: 1-Methyl-Tryptophan Can Interfere with TLR Signaling in Dendritic Cells Independently of IDO Activity
AUTHOR(S): Agaugue, Sophie; Perrin-Cocon, Laure; Coutant, Frederic; Andre, Patrice; Lotteau, Vincent
CORPORATE SOURCE: Institut National de la Sante et de la Recherche Medicale Unite 503, Institut Federatif de Recherche 128 Biosciences Lyon-Gerland, Universite Claude Bernard Lyon I, Lyon, Fr.
SOURCE: Journal of Immunology (2006), 177(4), 2061-2071
CODEN: JOIMA3; ISSN: 0022-1767
PUBLISHER: American Association of Immunologists
DOCUMENT TYPE: Journal
LANGUAGE: English

AB The compound 1-methyl-tryptophan (1-MT) is a competitive inhibitor of IDO that can break tolerance and induce fetus, graft, and tumor rejection. Because of its broad effect on immune-related mechanisms, the direct action of 1-MT on human monocyte-derived dendritic cells (DC) was analyzed. It is shown here that the effect of 1-MT on DC is dependent on the maturation pathway. Although 1-MT had no effect on DC stimulated by the TLR3 ligand poly(I:C), it strongly enhanced the Th1 profile of DC

stimulated with TLR2/1 or TLR2/6 ligands. Drastic changes in the function of DC stimulated by the TLR4 ligand LPS were induced by 1-MT. These cells could still activate allogeneic and syngeneic T cells but stimulation yielded T cells secreting IL-5 and IL-13 rather than IFN-γ. This action of 1-MT correlated with an increased phosphorylation of p38 and ERK MAPKs and sustained activation of the transcription factor c-Fos. Inhibiting p38 and ERK phosphorylation with synthetic inhibitors blocked the effect of 1-MT on LPS-stimulated DC. Thus, 1-MT can modulate DC function depending on the maturation signal and independently of its action on IDO. This is consistent with previous observations and will help further understanding the mechanisms of DC polarization.

REFERENCE COUNT: 58 THERE ARE 58 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:489852 CAPLUS
DOCUMENT NUMBER: 145:1023
TITLE: Modulators of dendritic cell IDO expression for treatment of immune-related disorders
INVENTOR(S): Albert, Matthew; Braun, Deborah
PATENT ASSIGNEE(S): Institut Pasteur, Fr.
SOURCE: U.S. Pat. Appl. Publ., 33 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006110371	A1	20060525	US 2005-251877	20051018
WO 2006056304	A2	20060601	WO 2005-EP11796	20051018
WO 2006056304	A3	20070125		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-629896P P 20041123

AB The invention relates to modulation of dendritic cells by controlling the expression and activity of indoleamine 2,3 dioxygenase for the treatment of cancers, inflammatory skin and lung disorders, and immunol. diseases. PGE2 plus TNF-α induced activation of IDO gene expression was shown to be mediated by the prostanoid receptor EP2, adenylate cyclase, and PKA in immature dendritic cells. The invention discloses the use of IDO expression in the screening of IDO inhibitors and in clin. anal. as a biomarker for the prediction of tumor invasiveness.

L4 ANSWER 8 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:387945 CAPLUS
DOCUMENT NUMBER: 144:404390
TITLE: Indolamine-2,3-dioxygenase inhibitors for modulation of immune regulation
INVENTOR(S): Pohl, Joerg; Niemeyer, Ulf
PATENT ASSIGNEE(S): Germany
SOURCE: Ger. Offen., 5 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent

LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102004050111	A1	20060427	DE 2004-102004050111	20041013
PRIORITY APPLN. INFO.:			DE 2004-102004050111	20041013

AB The invention discloses the therapeutic application of indolamine-2,3-dioxygenase (IDO) inhibitors for the treatment of diseases related to untimely IDO gene expression.

L4 ANSWER 9 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1019533 CAPLUS
DOCUMENT NUMBER: 141:420433
TITLE: Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities in the treatment of cancer and infection
INVENTOR(S): Munn, David; Mellor, Andrew
PATENT ASSIGNEE(S): Medical College of Georgia Research Institute, Inc., USA
SOURCE: U.S. Pat. Appl. Publ., 42 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2004234623	A1	20041125	US 2004-780797		20040217
US 2005186289	A1	20050825	US 2004-780150		20040217
PRIORITY APPLN. INFO.:			US 2003-459489P	P	20030401
			US 2004-538647P	P	20040122

AB The invention discloses a method for treating a subject with a cancer or an infection, the method including administering an inhibitor of indoleamine-2,3-dioxygenase (IDO) in an amount effective to reverse IDO-mediated immunosuppression, and administering at least one addnl. therapeutic agent, wherein the administration of the inhibitor of IDO and the at least one addnl. therapeutic agent demonstrate therapeutic synergy.

L4 ANSWER 10 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:927197 CAPLUS
DOCUMENT NUMBER: 141:388648
TITLE: Novel ido (indoleamine 2,3-dioxygenase) inhibitors and methods of use
INVENTOR(S): Prendergast, George C.; Muller, Alexander J.; Duhadaway, James B.; Malachowski, William
PATENT ASSIGNEE(S): Lankenau Institute for Medical Research, USA
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004094409	A1	20041104	WO 2004-US5154	20040220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2520586	A1	20041104	CA 2004-2520586	20040220
EP 1606285	A1	20051221	EP 2004-713430	20040220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1795187	A	20060628	CN 2004-80008331	20040220
CN 1794986	A	20060628	CN 2004-80014321	20040220
JP 2006521377	T	20060921	JP 2006-508788	20040220
US 2007173524	A1	20070726	US 2006-550444	20060601
PRIORITY APPLN. INFO.:			US 2003-458162P P	20030327
			US 2003-527449P P	20031205
			WO 2004-US5154 W	20040220

OTHER SOURCE(S): MARPAT 141:388648

AB Novel inhibitors of indoleamine 2,3-dioxygenase (IDO) activity are provided. In yet another embodiment of the present invention, a combination treatment protocol comprising administration of an IDO inhibitor with a signal transduction inhibitor (STI) or chemotherapeutic agent is provided, which is effective for suppressing tumor growth. In still another embodiment of the present invention, a combination treatment protocol is provided for the treatment of a chronic viral infection, comprising the administration of an IDO inhibitor and a chemotherapeutic agent.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:927043 CAPLUS
DOCUMENT NUMBER: 141:388646
TITLE: Novel methods for the treatment of cancer and viral infections
INVENTOR(S): Prendergast, George C.; Muller, Alexander J.; Duhadaway, James B.; Malachowski, William
PATENT ASSIGNEE(S): Lankenau Institute for Medical Research, USA
SOURCE: PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004093871	A1	20041104	WO 2004-US5155	20040220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2520172	A1	20041104	CA 2004-2520172	20040220
EP 1613308	A1	20060111	EP 2004-713378	20040220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1795187	A	20060628	CN 2004-80008331	20040220
CN 1794986	A	20060628	CN 2004-80014321	20040220
JP 2006521378	T	20060921	JP 2006-508789	20040220
US 2007099844	A1	20070503	US 2006-551151	20060518

PRIORITY APPLN. INFO.: US 2003-458162P P 20030327
US 2003-527449P P 20031205
WO 2004-US5155 W 20040220

AB Compns. and methods for the treatment of malignancy and chronic viral infection are disclosed. A method is claimed for treating a cancer comprising administering at least one indoleamine 2,3-dioxygenase (IDO) inhibitor and at least one signal transduction inhibitor (STI). A method is claimed for treating a cancer comprising administering at least one immunomodulator, other than IDO inhibitor, and at least one cytotoxic chemotherapeutic agent or at least one STI. A method for treating a chronic viral infection in a patient is claimed comprising administering at least one IDO inhibitor and at least one chemotherapeutic agent. Pharmaceutical compns. containing compds. of the invention for treating cancer and viral infections are also claimed.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:978994 CAPLUS
DOCUMENT NUMBER: 140:5035
TITLE: 3-Substituted beta-carboline derivatives having anti-HIV and antitumor activities
INVENTOR(S): Yang, Ming; Lin, Wei; Yu, Xiaolin; Xiao, Sulong; Li, Jingyun
PATENT ASSIGNEE(S): Peking Univ., Peop. Rep. China
SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 15 pp.
CODEN: CNXXEV
DOCUMENT TYPE: Patent
LANGUAGE: Chinese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1358720	A	20020717	CN 2001-144531	20011219

PRIORITY APPLN. INFO.: CN 2001-144531 20011219
OTHER SOURCE(S): CASREACT 140:5035; MARPAT 140:5035
GI



I

AB Title compds. I (R1 = COR4 or CONHR4; R2 = H, C1-6 alkyl, or COR4; R3 = H, C1-6 alkyl, or aryl-C1-6 alkyl; R4 = H, C1-6 alkyl, aryl, cycloalkyl, heterocyclic group, C1-6 alkylamino, C1-6 alkylguanidino, or di(C1-6 alkyl)amino; and R5, R6, R7, and/or R8 = H, halo, C1- 6 alkyl, hydroxy, C1-6 alkoxy, acyloxy, C1-6 acyl, aroyl, or aryl-C1-6 alkoxy) and their medical salts are synthesized by esterification of tryptophan derivative with methanol to obtain ester, Pictet-Spengler reaction with R2CHO to obtain 1,2,3,4-tetrahydro-9H-beta-carboline derivative, oxidation, and amidation. The carboline derivs. may be used as anti-HIV and antitumor agents and also as antioxidant in foods and drugs.

L4 ANSWER 13 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:818069 CAPLUS
DOCUMENT NUMBER: 139:322295
TITLE: Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
INVENTOR(S): Mellor, Andrew L.; Munn, David H.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 36 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2003194803	A1	20031016	US 2002-121909		20020412
CA 2483451	A1	20031023	CA 2002-2483451		20020412
WO 2003087347	A1	20031023	WO 2002-US11319		20020412
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
AU 2002307243	A1	20031027	AU 2002-307243		20020412
EP 1501918	A1	20050202	EP 2002-807233		20020412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
US 2006292618	A1	20061228	US 2006-474162		20060623
US 2007048769	A1	20070301	US 2006-474144		20060623
PRIORITY APPLN. INFO.:			US 2002-121909	A	20020412
			WO 2002-US11319	W	20020412

AB The disclosed invention is based on the discovery that antigen-presenting cells (APCs) may be generated to have predetd. levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunol. tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

L4 ANSWER 14 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2000:790660 CAPLUS
DOCUMENT NUMBER: 133:349121
TITLE: Methods for increasing T cell proliferation
INVENTOR(S): Van, Den Eynde Benoit; Bilsborough, Janine; Boon-Falleur, Thierry
PATENT ASSIGNEE(S): Ludwig Institute for Cancer Research, USA
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000066764	A1	20001109	WO 2000-US12118	20000503
W: AU, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1185687	A1	20020313	EP 2000-928796	20000503
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: US 1999-132219P P 19990503
WO 2000-US12118 W 20000503

AB The invention provides methods and compns. for increasing T cell proliferation using tryptophan enhancing agents. T cell proliferation can be increased in vitro by addition of tryptophan enhancing agents to T cell culture, or in vivo by administration of tryptophan enhancing agents. Also provided are methods for diagnosing and treating disorders characterized by constitutive expression of indoleamine-2,3-dioxygenase. Compns. and apparatus relating to the methods also are provided.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1999:388082 CAPLUS
DOCUMENT NUMBER: 131:35866
TITLE: Regulation of T cell-mediated immunity by tryptophan
INVENTOR(S): Munn, David; Mellor, Andrew
PATENT ASSIGNEE(S): Medical College of Georgia Research Institute, Inc., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9929310	A2	19990617	WO 1998-US25840	19981204
WO 9929310	A3	20000106		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9916285	A	19990628	AU 1999-16285	19981204
US 6395876	B1	20020528	US 1998-205939	19981204
US 6451840	B1	20020917	US 1998-206274	19981204
US 2001001040	A1	20010510	US 2000-727055	20001130
US 6482416	B2	20021119		
US 2002155104	A1	20021024	US 2002-112362	20020328
US 7160539	B2	20070109		
US 2007077224	A1	20070405	US 2006-602930	20061121
US 2007077234	A1	20070405	US 2006-603291	20061121

PRIORITY APPLN. INFO.: US 1997-67610P P 19971205
US 1998-80380P P 19980401
US 1998-80384P P 19980401
US 1998-206274 A3 19981204
WO 1998-US25840 W 19981204
US 2002-112362 A3 20020328

AB A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan

metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO (indoleamine 2,3-dioxygenase) can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO. Similarly, increasing tryptophan degradation (thereby, decreasing tryptophan concentration and increasing tryptophan metabolite concentration), for example, by increasing IDO concentration or IDO activity, can suppress T cells. Although described particularly with reference to IDO regulation, one can instead manipulate local tryptophan concns., and/or modulate the activity of the high affinity tryptophan transporter, and/or administer other tryptophan degrading enzymes. Regulation can be further manipulated using cytokines such as macrophage colony stimulating factor, interferon gamma, alone or in combination with antigen or other cytokines.

L4 ANSWER 16 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:597277 CAPLUS
DOCUMENT NUMBER: 123:83032
TITLE: Synthesis of 6-substituted indolactams by microbial conversion
AUTHOR(S): Irie, Kazuhiro; Iguchi, Maya; Oda, Tsuneyuki; Suzuki, Yoko; Okuno, Shigenori; Ohigashi, Hajime; Koshimizu, Koichi; Hayashi, Hideo; Arai, Motoo; et al.
CORPORATE SOURCE: Fac. Agric., Kyoto Univ., Kyoto, 606, Japan
SOURCE: Tetrahedron (1995), 51(22), 6255-66
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 123:83032
GI



I

AB New indolactam derivs. I (R2 = F, Br, iodo, Me) with a fluorine, bromine, iodine or Me group at position 6 of (-)-indolactam-V were synthesized from the corresponding seco-compds. (6-substituted N-methyl-L-valyl-L-tryptophanols) by the microbial conversion using Streptoverticillium blastomyceticum NA34-17. (-)-5-Fluoroindolactam-V and (-)-7-methylindolactam-V were similarly obtained by this method. (-)-6-Methylindolactam-V had almost the same biol. activities as (-)-7-methylindolactam-V, indicating that the substituent effect at position 6 of (-)-indolactam-V is similar to that at position 7.

L4 ANSWER 17 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1995:248281 CAPLUS

DOCUMENT NUMBER: 122:32008
TITLE: Preparation of tryptophan amides and analogs as tachykinin antagonists
INVENTOR(S): Horwell, David Christopher; Howson, William; Rees, David Charles; Roberts, Edward; Pritchard, Martyn Clive
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 147 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9404494	A1	19940303	WO 1993-US7552	19930812
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 655055	A1	19950531	EP 1993-919974	19930812
EP 655055	B1	20001129		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08500361	T	19960116	JP 1994-506383	19930812
JP 3507494	B2	20040315		
AU 687754	B2	19980305	AU 1993-50055	19930812
AU 9350055	A	19940315		
EP 1000930	A2	20000517	EP 2000-102502	19930812
EP 1000930	A3	20031029		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
AT 197793	T	20001215	AT 1993-919974	19930812
ES 2153841	T3	20010316	ES 1993-919974	19930812
PT 655055	T	20010330	PT 1993-919974	19930812
GR 3035372	T3	20010531	GR 2001-400199	20010206

PRIORITY APPLN. INFO.:	US 1992-930252	A	19920813
	US 1993-97264	A	19930723
	EP 1993-919974	A3	19930812
	WO 1993-US7552	W	19930812

OTHER SOURCE(S): MARPAT 122:32008
GI



I

AB RCR1R2XCR3[(CH2)nR8]Y(CR5R7)qR6 [R,R6,R8 = (un)substituted (hetero)aryl; R1,R2, R5,R7 = H, alkyl; RR2 = atoms to form a ring; R3 = H, (CH2)mR13; R13 = H, cyano, NH2, NMe2, NHAc; X = O2CNR11; R11 = H, alkyl; Y = CONR4, CO2, CH2O, CH2NH, CH:CH, etc.; R4 = H, alkyl; m = 1-6; n = 1-2] were prepared Thus, title compound I (preparation given) had ID50 of 0.051mg/kg i.v.

against substance P Me ester-induced plasma protein extravasation in guinea pig bladder.

L4 ANSWER 18 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1991:220909 CAPLUS
DOCUMENT NUMBER: 114:220909
TITLE: Investigations on the antiproliferative effects of amino acid antagonists targeting for aminoacyl-tRNA synthetases. Part III. Combination experiments
AUTHOR(S): Laske, Reiner; Schoenenberger, Helmut; Holler, Eggehard
CORPORATE SOURCE: Inst. Pharm., Univ. Regensburg, Regensburg, D-8400, Germany
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1991), 324(3), 153-60
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English
AB The combined effects of amino acid antagonists with proven or potential inhibitory activities on aminoacyl-tRNA synthetases were investigated on the murine leukemic cell line P388 D1. As the best result a summation of the antiproliferative effects was observed Combinations with established cytostatic agents like platinum complexes or other antitumor compds. also yielded partly additive effects. In expts. performed with asparaginase, L-aspartic acid-β-hydroxamate gave synergistic growth inhibition of P388 D1 cells in vitro, which was reflected by additive effects against murine leukemia P388 in vivo.

L4 ANSWER 19 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:111625 CAPLUS
DOCUMENT NUMBER: 112:111625
TITLE: Investigations on the antiproliferative effects of amino acid antagonists targeting for aminoacyl-tRNA synthetases. Part II. The antileukemic effect
AUTHOR(S): Laske, Reiner; Schoenenberger, Helmut; Holler, Eggehard
CORPORATE SOURCE: Inst. Pharm., Univ. Regensburg, Regensburg, D-8400, Fed. Rep. Ger.
SOURCE: Archiv der Pharmazie (Weinheim, Germany) (1989), 322(12), 857-62
CODEN: ARPMAS; ISSN: 0365-6233
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Amino acid antagonists with proven or potential inhibitory activities on aminoacyl-tRNA synthetases were tested for their antiproliferative effect against the murine leukemic cell line P338D1. Micromolar concns. of the compds. S-tritylcysteine, fenitropan, and β-chloroalanine were markedly inhibitory. In the mouse only S-tritylcysteine was effective against leukemia P388 (T/C = 211%). The inhibitory effect on aminoacyl-tRNA synthetases and the antiproliferative action on P388D1 or P388 could not be correlated.

L4 ANSWER 20 OF 38 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1988:4798 CAPLUS
DOCUMENT NUMBER: 108:4798
TITLE: Nitrosatable precursors of mutagens in vegetables and soy suace
AUTHOR(S): Nagao, Minako; Wakabayashi, Keiji; Fujita, Yuki; Tahira, Tomoko; Ochiai, Masako; Takayama, Shozo; Sugimura, Takashi
CORPORATE SOURCE: Carcinog. Div., Natl. Cancer Cent. Res. Inst., Tokyo, 104, Japan
SOURCE: Proceedings of the International Symposium of the Princess Takamatsu Cancer Research Fund (1986), Volume Date 1985, 16th(Diet, Nutr., Cancer), 77-86

CODEN: PPTCBY
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Nitrosatable precursors of mutagens that show mutagenicity to Salmonella typhimurium TA100 without S9 mix after treatment with nitrite at pH 3 were found in various foods. From Chinese cabbage, 3 indole compds., indole-3-acetonitrile, 4-methoxyindole-3-acetonitrile, and 4-methoxyindole-3-aldehyde, were identified as mutagen precursors. 1-Methylindole and 2-methylindole, present in cigarette smoke, had strong mutagen precursor activity. Escherichia coli WP2 uvrA/pKM101 is more sensitive than S. typhimurium TA100 to nitrostable precursors in soy sauce after treatment with 1-3 m nitrite. The mutagenicity of soy sauce towards E. coli WP2 uvrA/pKM101 is partly explained by 1-methyl-1,2,3,4-tetrahydro-β-carboline-3-carboxylic acid (MTCA) and tyramine. Oral administration of soy sauce and nitrite to male Fischer 344 rats for 2 yr induced basal cell proliferation of the forestomach and intestinal metaplasia of the glandular stomach, but did not induce cancers in any organ. 3-Diazotyramine, a mutagenic nitrosation product of tyramine present at high concns. in various foods, induced squamous cell carcinomas of the oral cavity of rats when given in their drinking water. The carcinogenesis by N-benzylmethylamine, nitrostable precursor and nitrite, was prevented by thioproline.

L4 ANSWER 21 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2007:198176 USPATFULL
TITLE: "Novel ido inhibitors and methods of use
INVENTOR(S): Prendergast, George C., Bala Cynwyd, PA, UNITED STATES
Muller, Alexander J., Media, PA, UNITED STATES
Duhadaway, James B., Wilmington, DE, UNITED STATES
Malachowski, William, Collegeville, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2007173524	A1	20070726	
APPLICATION INFO.:	US 2004-550444	A1	20040220	(10)
	WO 2004-US5154		20040220	
			20060601	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-458162P	20030327 (60)
	US 2003-527449P	20031205 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400, PHILADELPHIA, PA, 19103-2307, US
NUMBER OF CLAIMS: 37
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 31 Drawing Page(s)
LINE COUNT: 1893
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds, compositions and methods for the treatment of malignancy are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 22 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2007:114770 USPATFULL
TITLE: Novel methods for the treatment of cancer
INVENTOR(S): Prendergast, George C., Bala-Cynwyd, PA, UNITED STATES
Muller, Alexander J., Media, PA, UNITED STATES
Duhadaway, James B., Wilmington, DE, UNITED STATES
Malachowski, William, Collegeville, PA, UNITED STATES

	NUMBER	KIND	DATE

PATENT INFORMATION:	US 2007099844	A1	20070503
APPLICATION INFO.:	US 2004-551151	A1	20040220 (10)
	WO 2004-US5155		20040220
			20060518 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-458162P	20030327 (60)
	US 2003-527449P	20031205 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: DANN, DORFMAN, HERRELL & SKILLMAN, 1601 MARKET STREET, SUITE 2400, PHILADELPHIA, PA, 19103-2307, US
NUMBER OF CLAIMS: 52
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Page(s)
LINE COUNT: 1319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compositions and methods for the treatment of malignancy and chronic viral infection are disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 23 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2007:55827 USPATFULL
TITLE: Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
INVENTOR(S): Mellor, Andrew L., Martinez, GA, UNITED STATES
Munn, David H., Augusta, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007048769	A1	20070301
APPLICATION INFO.:	US 2006-474144	A1	20060623 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-121909, filed on 12 Apr 2002, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KILPATRICK STOCKTON LLP - M0351, 1001 WEST FOURTH STREET, WINSTON-SALEM, NC, 27101, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 2501
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 24 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2007:23191 USPATFULL

TITLE: Compositions and methods for cancer immunotherapy
INVENTOR(S): Rossignol, Daniel P., Ridgefield Park, NJ, UNITED STATES
Ishizaka, Sally T., Andover, MA, UNITED STATES
Hawkins, Lynn D., Andover, MA, UNITED STATES
Fields, Scott, Ridgefield Park, NJ, UNITED STATES
PATENT ASSIGNEE(S): Eisai Co., Ltd., Tokyo, JAPAN, 112-88 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2007020232	A1	20070125
APPLICATION INFO.:	US 2006-411332	A1	20060426 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-674680P	20050426 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: WILMER CUTLER PICKERING HALE AND DORR LLP, 60 STATE STREET, BOSTON, MA, 02109, US
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Page(s)
LINE COUNT: 1513
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to a subject individual to prevent or delay the development of cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 25 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2006:340837 USPATFULL
TITLE: Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
INVENTOR(S): Mellor, Andrew L., Martinez, GA, UNITED STATES
Munn, David H., Augusta, GA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006292618	A1	20061228
APPLICATION INFO.:	US 2006-474162	A1	20060623 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-121909, filed on 12 Apr 2002, PENDING
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KILPATRICK STOCKTON LLP - M0351, 1001 WEST FOURTH STREET, WINSTON-SALEM, NC, 27101, US
NUMBER OF CLAIMS: 20
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 2508
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase

tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 26 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2006:308802 USPATFULL
TITLE: Inhibitors of histone deacetylase
INVENTOR(S): Leit de Moradei, Silvana Marcela, Kirkland, CANADA
Tessier, Pierre, Hawkesbury, CANADA
Smil, David, Montreal, CANADA
Wahhab, Amal, Laval, CANADA
Deziel, Robert, Mount-Royal, CANADA
Manku, Sukhdev, L'lle Perrot, CANADA
Mancuso, John, Vaudreuil, CANADA
Therrien, Eric, Laval, CANADA
Allan, Martin, Montreal, CANADA
Chantigny, Yves Andre, Pincourt, CANADA
Ajamian, Alain, Montreal, CANADA
Beaulieu, Patrick, Laval, CANADA
PATENT ASSIGNEE(S): MethylGene Inc. (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006264415	A1	20061123
APPLICATION INFO.:	US 2006-395173	A1	20060331 (11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2005-667708P	20050401 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP, 300 S. WACKER DRIVE, 32ND FLOOR, CHICAGO, IL, 60606, US
NUMBER OF CLAIMS: 73
EXEMPLARY CLAIM: 1
LINE COUNT: 13021
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention relates to compounds for the inhibition of histone deacetylase. More particularly, the invention provides for compounds of formula (I) ##STR1## wherein Y, L, Z, W, X, Q, R.sub.1, R.sub.2 and R.sub.3 are as defined in the specification.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 27 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2006:130734 USPATFULL
TITLE: Control of indoleamine 2,3 deoxygenase expression and activity
INVENTOR(S): Albert, Matthew, Paris, FRANCE
Braun, Deborah, Paris, FRANCE
PATENT ASSIGNEE(S): INSTITUT PASTEUR, Paris, FRANCE (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2006110371	A1	20060525
APPLICATION INFO.:	US 2005-251877	A1	20051018 (11)

	NUMBER	DATE

PRIORITY INFORMATION:	US 2004-629896P	20041123 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C., 1940 DUKE STREET, ALEXANDRIA, VA, 22314, US	
NUMBER OF CLAIMS:	32	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	19 Drawing Page(s)	
LINE COUNT:	1251	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to controlling and/or manipulating of dendritic cells by controlling the expression and activity of indoleamine 2,3 deoxygenase expression and activity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 28 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2005:214617 USPATFULL		
TITLE:	Regulation of T cell-mediated immunity by D isomers of inhibitors of indoleamine-2,3-dioxygenase		
INVENTOR(S):	Munn, David, Augusta, GA, UNITED STATES Mellor, Andrew, Augusta, GA, UNITED STATES		
PATENT ASSIGNEE(S):	Medical College of Georgia Research Institute, Inc., Augusta, GA, UNITED STATES, 30912 (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005186289	A1	20050825
APPLICATION INFO.:	US 2004-780150	A1	20040217 (10)
	NUMBER		DATE
PRIORITY INFORMATION:	US 2004-538647P		20040122 (60)
	US 2003-459489P		20030401 (60)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN, 55458, US		
NUMBER OF CLAIMS:	47		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	19 Drawing Page(s)		
LINE COUNT:	2455		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides improved treatment methods by the administration of the non-physiologic D-isomer of an IDO inhibitor.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 29 OF 38 USPATFULL on STN

ACCESSION NUMBER:	2005:10969 USPATFULL		
TITLE:	Methods of precise molecular-level determination of ligand-receptor interactions and designing selective drug compounds based on said interactions		
INVENTOR(S):	Dougherty, Dennis A., South Pasadena, CA, UNITED STATES Lester, Henry A., South Pasadena, CA, UNITED STATES Shiva, Nima, Los Angeles, CA, UNITED STATES		
PATENT ASSIGNEE(S):	Neurion Pharmaceuticals, Pasadena, CA (U.S. corporation)		
	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2005009103	A1	20050113
APPLICATION INFO.:	US 2004-886742	A1	20040708 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-485773P	20030708 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834
NUMBER OF CLAIMS: 26
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 10 Drawing Page(s)
LINE COUNT: 1312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention discloses methods of determining highly precise interactions between a membrane protein receptor and various compounds. The methods of the present invention utilize a receptophore model system and nonsense codon suppression methods combined with heterologous in vivo expression in Xenopus oocytes.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 30 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2004:298760 USPATFULL
TITLE: Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
INVENTOR(S): Munn, David, Augusta, GA, UNITED STATES
Mellor, Andrew, Augusta, GA, UNITED STATES
PATENT ASSIGNEE(S): Medical College of Georgia Research Institute, Inc., Augusta, GA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2004234623	A1	20041125	
APPLICATION INFO.:	US 2004-780797	A1	20040217	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-538647P	20040122 (60)
	US 2003-459489P	20030401 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN, 55458
NUMBER OF CLAIMS: 43
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 19 Drawing Page(s)
LINE COUNT: 2338
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 31 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2003:276778 USPATFULL
TITLE: Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance
INVENTOR(S): Mellor, Andrew L., Martinez, GA, UNITED STATES
Munn, David H., Augusta, GA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003194803	A1	20031016	
APPLICATION INFO.:	US 2002-121909	A1	20020412	(10)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: Cynthia B. Rothschild, Esq., Kilpatrick Stockton LLP, 1001 West Fourth Street, Winston-Salem, NC, 27101
NUMBER OF CLAIMS: 114
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 9 Drawing Page(s)
LINE COUNT: 2852
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 32 OF 38 USPATFULL on STN
ACCESSION NUMBER: 2000:125101 USPATFULL
TITLE: Naphthyl compounds promote release of growth hormone
INVENTOR(S): Chen, Meng Hsin, Westfield, NJ, United States
Morriello, Gregori J., Belleville, NJ, United States
Nargund, Ravi, East Brunswick, NJ, United States
Patchett, Arthur A., Westfield, NJ, United States
Yang, Lihu, Edison, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6121325		20000919
APPLICATION INFO.:	US 1997-826290		19970327 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-398247, filed on 3 Mar 1995, now patented, Pat. No. US 5663171, issued on 2 Sep 1997 which is a continuation-in-part of Ser. No. WO 1994-US13596, filed on 23 Nov 1994 which is a continuation-in-part of Ser. No. US 1993-157774, filed on 24 Nov 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ambrose, Michael G.
LEGAL REPRESENTATIVE: Thies, J. Eric, Rose, David L.
NUMBER OF CLAIMS: 11
EXEMPLARY CLAIM: 1
LINE COUNT: 2345
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to certain compounds of the general structural formula: ##STR1## wherein R.sub.1, R.sub.1a, R.sub.2a, R.sub.3, R.sub.3a, R.sub.4, R.sub.5, R.sub.6, A, W, and n are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such compounds as the

active ingredient thereof are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 33 OF 38 USPATFULL on STN
ACCESSION NUMBER: 1999:142162 USPATFULL
TITLE: Tachykinin antagonists
INVENTOR(S): Horwell, David Christopher, Foxton, United Kingdom
Howson, William, Weston Colville, United Kingdom
Pritchard, Martyn Clive, St. Ives, United Kingdom
Roberts, Edward, Newmarket, United Kingdom
Rees, David Charles, Glasgow, United Kingdom
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5981755		19991109	
APPLICATION INFO.:	US 1998-168512		19981008	(9)

RELATED APPLN. INFO.: Division of Ser. No. US 1993-953037, filed on 17 Oct 1993, now patented, Pat. No. US 5856354 which is a division of Ser. No. US 1996-727067, filed on 8 Oct 1996, now patented, Pat. No. US 5716979 which is a division of Ser. No. US 1994-344064, filed on 29 Nov 1994, now patented, Pat. No. US 5594022 And a continuation-in-part of Ser. No. US 1993-97264, filed on 23 Jul 1993, now abandoned And a continuation-in-part of Ser. No. US 1992-930252, filed on 13 Aug 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Oswecki, Jane C.
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 2
EXEMPLARY CLAIM: 2
LINE COUNT: 3101
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns tachykinin antagonists. The compounds are nonpeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included. The compounds are expected to be especially useful in asthma and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 34 OF 38 USPATFULL on STN
ACCESSION NUMBER: 1999:92802 USPATFULL
TITLE: Dipeptides which promote release of growth hormone
INVENTOR(S): Carpino, Philip A., Groton, CT, United States
Dasilva-Jardine, Paul A., Providence, RI, United States
Lefker, Bruce A., Gales Ferry, CT, United States
Ragan, John A., Gales Ferry, CT, United States
PATENT ASSIGNEE(S): Pfizer Inc, New York, NY, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5936089		19990810	
	WO 9638471		19961205	
APPLICATION INFO.:	US 1997-973268		19971126	(8)
	WO 1995-IB410		19950529	
			19971126	PCT 371 date

19971126 PCT 102(e) date

DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Ramsuer, Robert W.
LEGAL REPRESENTATIVE: Richardson, Peter C., Ginsburg, Paul H., Speer, Raymond M.
NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
LINE COUNT: 5362
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Compounds of formula (I) are growth hormone releasing peptide mimetics which are useful for the treatment and prevention of osteoporosis. ##STR1##

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 35 OF 38 USPATFULL on STN
ACCESSION NUMBER: 1999:1685 USPATFULL
TITLE: Tachykinin antagonists
INVENTOR(S): Horwell, David Christopher, Foxton, England
Howson, William, Weston Colville, England
Pritchard, Martyn Clive, St. Ives, England
Roberts, Edward, Wood Ditton, England
Rees, David Charles, Glasgow, Scotland
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5856354		19990105
APPLICATION INFO.:	US 1997-953037		19971017 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-727067, filed on 8 Oct 1996, now patented, Pat. No. US 5716979 which is a division of Ser. No. US 1994-344064, filed on 29 Nov 1994, now patented, Pat. No. US 5594022 And a continuation-in-part of Ser. No. US 1993-97264, filed on 23 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-930252, filed on 13 Aug 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Oswecki, Jane C.
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 31
EXEMPLARY CLAIM: 1
LINE COUNT: 3351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns tachykinin antagonists. The compounds are neopeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included. The compounds are expected to be especially useful in asthma and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 36 OF 38 USPATFULL on STN
ACCESSION NUMBER: 1998:14826 USPATFULL
TITLE: Tachykinin antagonists
INVENTOR(S): Horwell, David Christopher, Foxton, England
Howson, William, Weston Colville, England
Pritchard, Martyn Clive, St. Ives, England
Roberts, Edward, Wood Ditton, England

Rees, David Charles, Glasgow, Scotland
PATENT ASSIGNEE(S): Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5716979		19980210
APPLICATION INFO.:	US 1996-727067		19961008 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1994-344064, filed on 29 Nov 1994, now patented, Pat. No. US 5594022 And a continuation-in-part of Ser. No. US 1993-97264, filed on 23 Jul 1993, now abandoned And a continuation-in-part of Ser. No. US 1992-930252, filed on 13 Aug 1992, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Richter, Johann
ASSISTANT EXAMINER: Oswecki, Jane C.
LEGAL REPRESENTATIVE: Anderson, Elizabeth M.
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
LINE COUNT: 3367
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention concerns tachykinin antagonists. The compounds are nonpeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included.

The compounds are expected to be especially useful in asthma and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 37 OF 38 USPATFULL on STN
ACCESSION NUMBER: 97:78440 USPATFULL
TITLE: Acyclic compounds promote release of growth hormone
INVENTOR(S): Chen, Meng Hsin, Westfield, NJ, United States
Morriello, Gregori J., Belleville, NJ, United States
Nargund, Ravi, East Brunswick, NJ, United States
Patchett, Arthur A., Westfield, NJ, United States
Yang, Lihu, Edison, NJ, United States
PATENT ASSIGNEE(S): Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5663171		19970902
APPLICATION INFO.:	US 1995-398247		19950303 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-157774, filed on 24 Nov 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Springer, David B.
LEGAL REPRESENTATIVE: Thies, J. Eric, Rose, David L.
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 2352
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The present invention is directed to certain compounds of the general structural formula: ##STR1## wherein R.sub.1, R.sub.1a, R.sub.2a, R.sub.3, R.sub.3a, R.sub.4, R.sub.5, R.sub.6, A, W, and n are as defined herein. These compounds promote the release of growth hormone in humans and animals. This property can be utilized to promote the growth of food

animals to render the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, such as short stature in growth hormone deficient children, and to treat medical conditions which are improved by the anabolic effects of growth hormone. Growth hormone releasing compositions containing such compounds as the active ingredient thereof are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 38 OF 38 USPATFULL on STN

ACCESSION NUMBER:	97:3869 USPATFULL
TITLE:	Tachykinin antagonists
INVENTOR(S):	Horwell, David C., Foxton, England Howson, William, Weston Colville, England Pritchard, Martyn C., St. Ives, England Roberts, Edward, Wood Ditton, England Rees, David C., Glasgow, Scotland
PATENT ASSIGNEE(S):	Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5594022		19970114
APPLICATION INFO.:	US 1994-344064		19941129 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-97264, filed on 23 Jul 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-930252, filed on 13 Aug 1992, now abandoned

DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Springer, David B.
LEGAL REPRESENTATIVE:	Anderson, Elizabeth M.
NUMBER OF CLAIMS:	51
EXEMPLARY CLAIM:	1
LINE COUNT:	3534

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns tachykinin antagonists. The compounds are nonpeptides which have utility in treating disorders mediated by tachykinins. Such disorders are respiratory, inflammatory, gastrointestinal, ophthalmic, allergies, pain, vascular, diseases of the central nervous system, and migraine. Methods of preparing compounds and novel intermediates are also included.

The compounds are expected to be especially useful in asthma and rheumatoid arthritis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 10:50:11 ON 06 DEC 2007)

FILE 'REGISTRY' ENTERED AT 10:50:37 ON 06 DEC 2007
L1 STRUCTURE UPLOADED
L2 8 S L1 FULL

FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 10:51:25 ON 06 DEC 2007
L3 204 S L2
L4 38 S L3 AND (CANCER? OR TUMOR? OR NEOPLAS?)
L5 10 S L4 AND CYCLOPHOSPHAMIDE

=>

---Logging off of STN---

=>
Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	169.34	341.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-19.50	-19.50

STN INTERNATIONAL LOGOFF AT 10:57:14 ON 06 DEC 2007